Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Ovarian Neoplasms 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Brain Neoplasms 2Peripheral Nervous System Diseases 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Melanoma × sagopilone × Clear all
NCT00598507 2013-12-11

Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
35 enrolled 8 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡